<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <title>MANDEVAL – Technical appendix</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <style>
    :root {
      --bg-page: #f5f7fa;
      --bg-card: #ffffff;
      --border-subtle: #d2d6dc;
      --text-main: #111827;
      --text-muted: #6b7280;
      --primary: #1f6feb;
    }

    * {
      box-sizing: border-box;
    }

    body {
      margin: 0;
      padding: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
      color: var(--text-main);
      background: var(--bg-page);
    }

    .page {
      max-width: 900px;
      margin: 20px auto;
      padding: 0 14px 20px 14px;
    }

    header {
      padding: 10px 0 2px 0;
      border-bottom: 3px solid var(--primary);
      margin-bottom: 12px;
    }

    header h1 {
      margin: 0;
      font-size: 1.4rem;
    }

    header p {
      margin: 2px 0 0 0;
      font-size: 0.85rem;
      color: var(--text-muted);
    }

    h2 {
      margin-top: 16px;
      margin-bottom: 6px;
      font-size: 1.1rem;
    }

    h3 {
      margin-top: 12px;
      margin-bottom: 4px;
      font-size: 0.98rem;
    }

    p {
      margin: 4px 0;
      font-size: 0.9rem;
    }

    ul {
      margin: 4px 0 6px 18px;
      font-size: 0.9rem;
    }

    .card {
      background: var(--bg-card);
      border-radius: 10px;
      padding: 12px 14px;
      border: 1px solid var(--border-subtle);
      margin-bottom: 10px;
    }

    .pill {
      display: inline-block;
      padding: 2px 8px;
      border-radius: 999px;
      background: #e5f0ff;
      color: #0b3d91;
      font-size: 0.7rem;
      font-weight: 600;
      text-transform: uppercase;
      letter-spacing: 0.04em;
    }

    .grid-2 {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(260px, 1fr));
      gap: 10px;
    }

    .highlight {
      background: #ecf5ff;
      border-left: 3px solid #1557bf;
      padding: 6px 8px;
      font-size: 0.9rem;
      border-radius: 4px;
    }

    table {
      width: 100%;
      border-collapse: collapse;
      font-size: 0.82rem;
      margin-top: 4px;
    }

    table th,
    table td {
      border: 1px solid #e5e7eb;
      padding: 3px 4px;
      text-align: left;
    }

    table thead {
      background: #f3f4f6;
    }

    .small {
      font-size: 0.8rem;
      color: var(--text-muted);
    }

    .tag {
      display: inline-block;
      font-size: 0.72rem;
      padding: 1px 6px;
      border-radius: 6px;
      background: #e5e7eb;
      margin-right: 4px;
      margin-bottom: 2px;
    }

    .changelog {
      font-size: 0.82rem;
    }

    @media print {
      body {
        background: #ffffff;
      }
      .card {
        box-shadow: none;
      }
    }
  </style>
</head>
<body>
  <div class="page">
    <header>
      <h1>MANDEVAL – Technical appendix</h1>
      <p>Methods, parameters and guidance for the vaccine mandate decision aid (Australia, France, Italy).</p>
      <p class="small">Version v1.0.0 &nbsp;|&nbsp; Built Jan 2026</p>
    </header>

    <section class="card">
      <span class="pill">Overview</span>
      <h2>1. Purpose and scope</h2>
      <p>
        This appendix documents the main inputs, modelling assumptions and outputs used in MANDEVAL, a decision aid for
        exploring the consequences of different COVID-19 vaccine mandate designs in Australia, France and Italy.
      </p>
      <p>
        MANDEVAL combines preference estimates from a discrete choice experiment (DCE) with simple epidemiological and
        costing inputs to provide:
      </p>
      <ul>
        <li>Model-based predicted public support for a given mandate configuration.</li>
        <li>Expected lives saved in the exposed population, based on a “lives saved per 100,000” input.</li>
        <li>Monetary valuation of lives saved, using a value per life saved (for example a value of statistical life).</li>
        <li>Implementation costs and resulting net benefit and benefit–cost ratios.</li>
        <li>“Lives-saved equivalents” (MRS) to interpret preferences over mandate design features.</li>
      </ul>
    </section>

    <section class="card">
      <span class="pill">Non-technical</span>
      <h2>2. How the tabs fit together</h2>
      <div class="grid-2">
        <div>
          <h3>2.1. Settings</h3>
          <p>
            The Settings tab defines the population, analysis horizon and value per life saved. These apply to all
            scenarios:
          </p>
          <ul>
            <li><strong>Analysis horizon:</strong> number of years during which costs and benefits are considered.</li>
            <li><strong>Population covered:</strong> number of people exposed to the mandate.</li>
            <li>
              <strong>Value per life saved:</strong> a monetary value attached to one life saved, aligned with national
              regulatory guidance where possible.
            </li>
          </ul>

          <h3>2.2. Mandate configuration</h3>
          <p>
            The Configuration tab selects the country, outbreak scenario and design features of the mandate (scope,
            exemptions, coverage threshold, expected lives saved). The preference model then calculates the predicted
            probability that people would support this mandate over no mandate.
          </p>
        </div>
        <div>
          <h3>2.3. Costing</h3>
          <p>
            The Costing tab allows users to enter indicative implementation costs across several categories (digital
            systems, communications, enforcement, compensation, administration and other costs). These are summed into a
            total implementation cost.
          </p>
          <h3>2.4. Results</h3>
          <p>
            The Results tab combines preference-based support, epidemiological inputs and costs to produce:
          </p>
          <ul>
            <li>Total lives saved in the exposed population.</li>
            <li>Monetary value of lives saved.</li>
            <li>Total implementation cost, net benefit and benefit–cost ratio.</li>
            <li>
              Lives-saved equivalents (MRS) that interpret changes in mandate features in terms of “equivalent lives saved
              per 100,000 people”.
            </li>
          </ul>
          <p>
            Status chips indicate whether predicted support and the benefit–cost ratio appear high, medium or low, based
            on transparent thresholds.
          </p>
        </div>
      </div>
      <p>
        The Saved scenarios tab stores complete scenarios (settings, configuration, costs and results) for comparison and
        export, while the Briefings &amp; AI prompts tab helps users translate scenarios into short policy briefings or
        prompts for Copilot / ChatGPT.
      </p>
    </section>

    <section class="card">
      <span class="pill">Interpretation</span>
      <h2>3. Predicted public support</h2>
      <p>
        MANDEVAL reports “predicted public support” as the model-based probability that a respondent would choose a given
        mandate over an opt-out (no mandate) option, conditional on the country and outbreak frame.
      </p>
      <p>
        The underlying utility functions are:
      </p>
      <ul>
        <li><strong>U(mandate):</strong> utility from a mandate with specific scope, exemptions, coverage and lives saved.</li>
        <li><strong>U(opt-out):</strong> utility from the “no mandate” option.</li>
      </ul>
      <p class="highlight">
        For a given vector of random preferences β, the model­based probability of choosing the mandate is:
        <br />
        <em>P(mandate | β) = exp(U(mandate; β)) / [exp(U(mandate; β)) + exp(U(opt-out; β))]</em>.
      </p>
      <p>
        In MANDEVAL, preferences β are assumed to follow a multivariate normal distribution, estimated separately for each
        country and outbreak frame. The predicted probability used in the tool is the average of P(mandate | β) over
        1,000 draws from this distribution, using a fixed random seed for reproducibility.
      </p>
      <p class="small">
        Interpretation: a predicted support of 65% means that, under the stated conditions and extrapolating from the
        DCE, around two thirds of respondents would choose the mandate over no mandate. It is not a forecast of
        compliance or turnout and should be interpreted as an indicative acceptability measure.
      </p>
    </section>

    <section class="card">
      <span class="pill">Methods</span>
      <h2>4. Discrete choice experiment and mixed logit models</h2>
      <h3>4.1. Attributes and levels</h3>
      <p>
        The DCE asked respondents to choose between two mandate options and an opt-out alternative. Mandates were
        described using:
      </p>
      <ul>
        <li>Scope (high-risk occupations only vs all occupations &amp; public spaces).</li>
        <li>Exemption policy (medical only; medical + religious; medical + religious + personal belief).</li>
        <li>Coverage threshold to lift the mandate (50%, 70% or 90% of the population vaccinated).</li>
        <li>Expected lives saved per 100,000 people (10, 25, 35 or 40).</li>
      </ul>

      <h3>4.2. Mixed logit specification</h3>
      <p>
        For each country (Australia, France, Italy) and outbreak frame (mild / endemic, severe), a mixed logit (random
        parameters logit) model was estimated with normally distributed random coefficients:
      </p>
      <ul>
        <li>ASC for Policy A (mandate alternative).</li>
        <li>ASC for opt-out (no mandate).</li>
        <li>Dummy variables for scope, exemptions and coverage threshold levels.</li>
        <li>A continuous coefficient for expected lives saved per 100,000 people.</li>
      </ul>

      <p>
        The tool uses the estimated means and standard deviations of these random coefficients to generate 1,000 draws
        from a multivariate normal distribution (using independent normals for each parameter). For each draw, utilities
        for the mandate and opt-out options are computed at the chosen configuration, and the logit probability of
        supporting the mandate is calculated. The mean of these probabilities across draws is reported as “predicted
        public support”.
      </p>

      <h3>4.3. Coefficient tables used in the tool</h3>
      <p>
        The table below illustrates the structure of the mean coefficients used in MANDEVAL (values correspond to the
        mixed logit estimates imported into the tool).
      </p>

      <table>
        <thead>
          <tr>
            <th>Country / frame</th>
            <th>ASC Policy A</th>
            <th>ASC Opt-out</th>
            <th>Scope all</th>
            <th>Exemptions med+rel</th>
            <th>Exemptions med+rel+personal</th>
            <th>Coverage 70%</th>
            <th>Coverage 90%</th>
            <th>Lives saved (per 100k)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>Australia, mild</td>
            <td>0.464</td>
            <td>−0.572</td>
            <td>−0.319</td>
            <td>−0.157</td>
            <td>−0.267</td>
            <td>0.171</td>
            <td>0.158</td>
            <td>0.072</td>
          </tr>
          <tr>
            <td>Australia, severe</td>
            <td>0.535</td>
            <td>−0.694</td>
            <td>0.190</td>
            <td>−0.181</td>
            <td>−0.305</td>
            <td>0.371</td>
            <td>0.398</td>
            <td>0.079</td>
          </tr>
          <tr>
            <td>Italy, mild</td>
            <td>0.625</td>
            <td>−0.238</td>
            <td>−0.276</td>
            <td>−0.176</td>
            <td>−0.289</td>
            <td>0.185</td>
            <td>0.148</td>
            <td>0.039</td>
          </tr>
          <tr>
            <td>Italy, severe</td>
            <td>0.799</td>
            <td>−0.463</td>
            <td>0.174</td>
            <td>−0.178</td>
            <td>−0.207</td>
            <td>0.305</td>
            <td>0.515</td>
            <td>0.045</td>
          </tr>
          <tr>
            <td>France, mild</td>
            <td>0.899</td>
            <td>0.307</td>
            <td>−0.160</td>
            <td>−0.121</td>
            <td>−0.124</td>
            <td>0.232</td>
            <td>0.264</td>
            <td>0.049</td>
          </tr>
          <tr>
            <td>France, severe</td>
            <td>0.884</td>
            <td>0.083</td>
            <td>−0.019</td>
            <td>−0.192</td>
            <td>−0.247</td>
            <td>0.267</td>
            <td>0.398</td>
            <td>0.052</td>
          </tr>
        </tbody>
      </table>

      <p class="small">
        The standard deviations of these coefficients are also used to generate random draws, and follow the mixed logit
        estimates provided in the main analysis.
      </p>
    </section>

    <section class="card">
      <span class="pill">Costs &amp; benefits</span>
      <h2>5. Cost taxonomy and value per life saved</h2>
      <h3>5.1. Cost categories</h3>
      <p>
        The costing framework in MANDEVAL is designed to mirror standard components used in regulatory impact analyses
        for vaccine mandates and similar public health measures. It includes:
      </p>
      <ul>
        <li>Digital systems &amp; infrastructure (IT platforms, certificates, registries, integration).</li>
        <li>Communications &amp; public information (campaigns, materials, stakeholder engagement).</li>
        <li>Enforcement &amp; compliance (inspection, enforcement staff, penalties administration).</li>
        <li>Adverse-event monitoring &amp; compensation (pharmacovigilance and compensation schemes).</li>
        <li>Administration &amp; programme management (design, legal, coordination, oversight).</li>
        <li>Other mandate-specific costs (residual category for context-specific items).</li>
      </ul>
      <p>
        Users can adapt these values based on country-specific data, financial reports or regulatory impact assessments.
      </p>

      <h3>5.2. Value per life saved</h3>
      <p>
        The tool applies a single value per life saved to monetise the estimated lives saved. In practice, this is often
        anchored in:
      </p>
      <ul>
        <li>A value of statistical life (VSL) used in national regulatory guidance.</li>
        <li>A value of a statistical life-year (VSLY), where appropriate for age-structured analyses.</li>
        <li>
          Programme-specific willingness-to-pay thresholds (for example cost-effectiveness thresholds used in health
          technology assessment).
        </li>
      </ul>
      <p class="highlight">
        Users should align the value per life saved with relevant national or institutional guidance, and document the
        chosen value and source when using MANDEVAL in formal policy analysis.
      </p>
    </section>

    <section class="card">
      <span class="pill">Worked examples</span>
      <h2>6. Worked examples (illustrative)</h2>
      <p>
        This section illustrates how to follow a configuration through the tool. The numbers below are examples and should
        be replaced by country-specific inputs when used in practice.
      </p>

      <h3>6.1. Italy, severe outbreak</h3>
      <ul>
        <li><strong>Settings:</strong> population = 5,000,000; value per life saved = EUR 5,000,000; horizon = 1 year.</li>
        <li>
          <strong>Configuration:</strong> scope = all occupations &amp; public spaces; exemptions = medical + religious;
          coverage threshold = 70%; expected lives saved = 25 per 100,000 people.
        </li>
        <li>
          <strong>Costing:</strong> digital systems = EUR 8m; communications = EUR 3m; enforcement = EUR 10m;
          compensation = EUR 4m; administration = EUR 2m; other = EUR 3m (illustrative figures).
        </li>
      </ul>
      <p>
        The tool translates this into a total lives saved figure, monetary benefit of lives saved, total implementation
        cost, net benefit, benefit–cost ratio and predicted support. Status chips and charts highlight whether support and
        BCR appear high, medium or low, given the assumptions.
      </p>

      <h3>6.2. Australia, mild</h3>
      <p>
        An analogous example can be constructed for Australia under the mild frame, using a population (for example
        25,000,000), locally appropriate cost inputs and a value per life saved consistent with Australian regulatory
        guidance.
      </p>

      <h3>6.3. France, mild</h3>
      <p>
        A further example can be built for France in the mild frame, illustrating differences in predicted support across
        the three countries for similar policy designs.
      </p>
    </section>

    <section class="card">
      <span class="pill">Governance</span>
      <h2>7. Versioning and quality control</h2>
      <p>
        MANDEVAL has been structured to make updates transparent and auditable. The footer in the main application shows
        the version number and build date. This appendix includes a short changelog.
      </p>

      <h3>7.1. Internal quality checks</h3>
      <p>
        Before publication, a small grid of test scenarios is defined and evaluated using both MANDEVAL and the original
        estimation environment (for example MATLAB or R). Predicted support, lives saved, benefit–cost metrics and
        lives-saved equivalents are cross-checked to ensure the web implementation reproduces the reference calculations
        up to expected rounding differences.
      </p>

      <h3>7.2. Changelog</h3>
      <ul class="changelog">
        <li>
          <span class="tag">v1.0.0</span>
          First stable release of MANDEVAL. Integrated mixed logit preference estimates with a fixed set of 1,000 normal
          draws. Implemented settings, configuration, costing, results, scenario storage and briefing exports. Added
          lives-saved-equivalent (MRS) interpretations, status chips and an AI-assisted briefing prompt.
        </li>
      </ul>
    </section>
  </div>
</body>
</html>
